One of the biggest meetings of the world’s cancer specialists took place this weekend. Usually located in Chicago, researchers and clinicians around the world met virtually this year to present the latest in cancer research at the American Society of Clinical Oncology (ASCO) annual meeting. Here’s a flavour of the some of the top research presented.
A potentially life-extending treatment for some people with non small cell lung cancer (NSCLC) will now be available on the NHS in England.
The three latest SMC decisions will provide new treatment options for some adults with non small cell lung cancer, multiple myeloma and a rare type of lymphoma.
The National Institute for Health and Care Excellence has approved the drug osimertinib to treat some adults in England with untreated, advanced lung cancer.
The Scottish Medicines Consortium (SMC) has accepted 3 new cancer treatments for NHS use in Scotland
Adults in England with advanced lung cancer will not have access to a new targeted cancer drug, lorlatinib (Lorviqua).
Combining an immunotherapy with chemotherapy has been recommended as a treatment for some patients with lung cancer on the NHS in England.
One kidney cancer treatment and two lung cancer drugs have been recommended for use on the NHS in Scotland.
A treatment combination has been provisionally rejected for people with certain types of lung cancer on the NHS in England.